Search Bar & Filters
Found 235 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and diagnostic effectiveness of 18FFT8 PET imaging for detecting AL amyloidosis, focusing on its ability to directly visualize amyloid deposits in heart tissue. The study compares this new imaging approach with established methods such as echocardiography, contrast-enhanced MRI, and various laboratory tests to better differentiate AL amyloidosis from other conditions. Participants will receive a single intravenous injection of 10 3 mCi of 18FFT8, followed by a PETCT scan to assess organ uptake using standardized uptake values SUV. The study includes both patients with suspected or diagnosed cardiac amyloidosis and healthy volunteers. Clinical assessments and laboratory tests, including physical exams and evaluations of cardiac, liver, and kidney function, will be done before and after the scan to monitor safety and biodistribution. During the study, participants will undergo a single PETCT scan session and related clinical evaluations. Researchers will monitor safety from the time of injection up to seven days afterward and analyze the radiation dosage and biodistribution of 18FFT8. The total participation involves initial assessments, the scan, and follow-up safety monitoring, with data collected primarily on the imaging results and participant well-being.
Actively Recruiting
Healthy Volunteer
Researchers are studying a new imaging tracer called 18FNIDF to detect abnormal tau protein buildup in the brains of people with neurodegenerative diseases, including Alzheimers disease and related tauopathies. This study focuses on evaluating the safety and diagnostic ability of 18FNIDF PET imaging in living human brains, aiming to improve visualization of tau pathology compared to existing tracers. The research is sponsored by Tianjin Medical University. Participants receive a single intravenous injection of about 10 3 mCi of 18FNIDF, followed by a PETCT scan to track the tracers distribution in the brain. The study includes both healthy volunteers and patients with cognitive impairments, such as probable Alzheimers disease or other dementias. The imaging is done once, and safety is monitored up to 7 days after injection. During the study, participants will be observed for any side effects and undergo a PETCT scan to assess how well the tracer binds to tau proteins. Researchers will measure safety from the time of injection up to one week later and evaluate the diagnostic performance within two weeks of scanning. The total participation period includes the imaging day and follow-up safety assessments, with the study running until December 2030.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.
Actively Recruiting
Researchers are evaluating the efficacy and safety of B007 in adults with generalized myasthenia gravis, a condition characterized by muscle weakness. This randomized, double-blind, placebo-controlled trial is sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd and aims to better understand how B007 may impact the daily activities affected by this condition. Participants will receive either B007 or a matching placebo through subcutaneous injections on days 1 and 15. The study includes different dose levels of B007 and compares outcomes over approximately 16 weeks for the primary measure, with additional assessments extending to about 24 weeks and safety monitoring for up to one year. Throughout the trial, participants will be monitored for changes in their myasthenia gravis symptoms using specific scales such as MG-ADL, QMG, MGQoL15r, and MGC. Researchers will also track any treatment-emergent adverse events. Participants are expected to maintain stable doses of their standard care treatments during the study, and the trial will last until the end of 2026, including follow-up periods for comprehensive safety and efficacy assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called B007 compared to cyclosporine in treating adults with primary membranous nephropathy, a kidney condition. This study is a multicenter, randomized, controlled, open-label trial conducted in phases II and III to better understand treatment options for this disease. Participants will be randomly assigned to receive either B007 or cyclosporin capsules. B007 is given by subcutaneous injection on days 1 and 15, while cyclosporin capsules are taken orally at a dose of 3.5 mg per kg of body weight per day. The study will observe participants over about two years to assess remission rates and monitor safety. During the trial, participants will undergo laboratory tests and assessments to track overall, complete, and partial remission rates. Researchers will also monitor any treatment-emergent adverse events or serious side effects. Participants must meet specific kidney function criteria and will be followed closely throughout the study period until its completion in late 2026.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Recombinant Botulinum Toxin Type A YY001 injections for treating upper limb spasticity in adults who have had a stroke. This randomized, double-blind, multi-center phase IIIII study compares YY001 with BOTOX4 and a placebo to better understand treatment options for this condition. Participants will receive a single intramuscular injection of either Recombinant Botulinum Toxin Type A YY001 with a dose of 200-400 units, BOTOX4 with a dose of 200 units, or a placebo prepared with saline. The study includes three groups the experimental group receiving YY001, an active-controlled group receiving BOTOX4, and a placebo-controlled group. Each participant receives only one injection during the treatment period. During the study, participants will be monitored at 1, 4, 8, and 12 weeks after treatment through assessments such as the Modified Ashworth Scale MAS for spasticity, Physicians Global Assessment, and Disability Assessment Scale DAS. Researchers will also track any adverse events and the presence of antibodies to the treatment. The primary outcome is the change in MAS score at week 4. The study lasts at least 12 weeks with ongoing safety and efficacy follow-up.
Actively Recruiting
Researchers are studying LBL-034 in patients with relapsed or refractory multiple myeloma RRMM and plasma cell leukemia PCL to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and effectiveness. This open-label, multicenter phase III study includes dose escalation and dose expansion phases to find the recommended dose and dosing schedule. The trial aims to assess treatment response and adverse events in these patients. LBL-034 is given as an intravenous infusion every two weeks. The phase I study involves dose escalation to assess safety and tolerability, including a dose-limiting toxicity observation period lasting four weeks after the first full dose. After determining the recommended phase 2 dose RP2D, the phase II study evaluates efficacy across four patient cohorts, with dosing regimens based on phase I data. Biological samples are collected throughout for additional testing. Participants will be monitored for treatment response, drug levels, immune reaction, and side effects from the time they consent until 30 to 90 days after stopping the drug. Evaluation includes measurement of objective response rate, dose-limiting toxicities, maximum tolerated dose, adverse events, and other key outcomes such as minimal residual disease and soluble BCMA levels. The study will enroll approximately 342 patients and continues until 2027.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQH3906 capsules, a once-daily oral medication, in adults aged 18 to 75 with moderate to severe plaque psoriasis. This multicenter, randomized, double-blind, placebo- and active-controlled Phase III trial compares TQH3906 with deucravacitinib and placebo. TQH3906 selectively inhibits TYK2, targeting inflammatory pathways involved in psoriasis, aiming to support its approval for treating this condition. Participants are randomly assigned in a 221 ratio to receive TQH3906 capsules 24 mg, deucravacitinib tablets 6 mg, or placebos matching each drug during a 16-week double-blind treatment phase. After this, all participants enter a 36-week open-label extension where they receive TQH3906 capsules alone. Following treatment, there is a 4-week safety follow-up period to monitor any lasting effects. Throughout the study, participants undergo regular assessments including the static Physicians Global Assessment sPGA and Psoriasis Area and Severity Index PASI to measure skin improvement up to 16 and 52 weeks. Additional evaluations focus on scalp, nail, and palmoplantar psoriasis, quality of life via the Dermatology Life Quality Index DLQI, and drug levels in the body. Safety is closely monitored during and after the treatment periods to gather comprehensive data over a year.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of TQB3019 capsules in adults with advanced malignant tumors. This Phase 1 clinical trial uses a single-center, open, non-randomized, single-arm design to study patients with recurrent or refractory hematological cancers. Participants must meet specific health criteria, including physical status and organ function, to join the study. Participants receive TQB3019 capsules orally once daily, with doses ranging from 25 to 600 mg depending on the group. The trial includes two phases dose escalation and dose expansion. Treatment cycles last 28 days, and dosing may be single or continuous. The study monitors various outcomes such as dose limiting toxicity, maximum tolerated dose, and recommended phase II dose, along with adverse events and response rates. During the trial, participants undergo regular assessments including pharmacokinetic sampling at multiple time points, evaluation of protein levels, and monitoring of adverse effects up to about three years. Researchers measure overall response rates, disease control, progression-free survival, and overall survival. Safety is closely tracked from the first dose until 28 days after the last dose or other anti-tumor treatments begin. The total study duration extends to approximately three years with ongoing follow-up.
Actively Recruiting
Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.
1-10 of 235
1